Von Hippel-Lindau is Associated to Pancreatic Neuroendocrine Tumors: A Comprehensive Review

Main Article Content

Danilo Coco https://orcid.org/0000-0002-5839-1767
Silvana Leanza https://orcid.org/0000-0001-8672-7486


pancreatic neuroendocrine tumors (pNETs), surgery, Von Hippel-Lindau (VHL)


Multiorgan tumors are a hallmark of the autosomal dominant genetic disorder known as Von Hippel-Lindau syndrome (VHL), which is typically the result of inherited aberrations of the VHL tumor suppressor gene. The most frequent cancer is retinoblastoma, which can also occur in the brain and spinal cord, renal clear cell carcinoma (RCCC), paraganglioma, and neuroendocrine tumors. There may also be lymphangiomas, epididymal cysts, and pancreatic cysts or pancreatic neuroendocrine tumors (pNETs). The most frequent causes of death are metastasis from RCCC and neurological complications from retinoblastoma or central nervous system (CNS). Pancreatic cysts are present in 35–70% of VHL patients. Simple cysts, serous cysts, or pNETs are possible presentations, and the likelihood of malignant degeneration or metastasis is no greater than 8%. Although VHL has been associated with pNETs, their pathological characteristics are unknown. Furthermore, it is unknown whether variations in the VHL gene cause the development of pNETs. Hence, this retrospective study was undertaken with the main aim to examine whether pNETs are connected to VHL from a surgical perspective.

Abstract 333 | PDF Downloads 763 HTML Downloads 49 XML Downloads 10


1. Feletti A, Anglani M, Scarpa B, Schiavi F, Boaretto F, Zovato S et al. Von Hippel-Lindau disease: An evaluation of natural history and functional disability. Neuro-Oncology. 2016;18(7):1011–20. 10.1093/neuonc/nov313

2. Dwyer DC, Tu RK. Genetics of von Hippel-Lindau disease. AJNR Am J Neuroradiol. 2017;38(3):469–70. 10.3174/ajnr.A5032

3. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM et al. Von Hippel-Lindau disease. Lancet. 2003;361:2059–67. 10.1016/S0140-6736(03)13643-4

4. Seizinger BR, Rouleau GA, Ozelius LJ, Lane AH, Farmer GE, Lamiell JM, et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature. 1988;332(6161):268–9. 10.1038/332268a0

5. Wilding A, Ingham SL, Lalloo F, Clancy T, Huson SM, Moran A et al. Life expectancy in hereditary cancer predisposing diseases: An observational study. J Med Genet. 2012;49(4):264–9. 10.1136/jmedgenet-2011-100562

6. Poulsen ML, Budtz-Jørgensen E, Bisgaard ML. Surveillance in von Hippel-Lindau disease (VHL). Clin Genet. 2010;77(1):49–59. 10.1111/j.1399-0004.2009.01281.x

7. Maher ER. Von Hippel-Lindau disease. Eur J Can. 1994;30(13): 1987–90. 10.1016/0959-8049(94)00391-H

8. Coco D, Leanza S. Von Hippel-Lindau syndrome: Medical syndrome or surgical syndrome? A surgical perspective. J Kidney Cancer VHL. 2022;9(1):27–32. 10.15586/jkcvhl.v9i1.206

9. Woodward ER, Maher ER. Von Hippel-Lindau disease and endocrine tumour susceptibility. Endocr Relat Cancer. 2006;13(2):415–25. 10.1677/erc.1.00683

10. de Mestier L, Gaujoux S, Cros J, Hentic O, Vullierme MP, Couvelard A et al. Long-term prognosis of resected pancreatic neuroendocrine tumors in von Hippel-Lindau disease is favorable and not influenced by small tumors left in place. Ann Surg. 2015;262(2):384–8. 10.1097/SLA.0000000000000856

11. Krauss T, Ferrara AM, Links TP, Wellner U, Bancos I, Kvachenyuk A et al. Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2018;25(9):783–93. 10.1530/ERC-18-0100

12. Libutti SK, Choyke PL, Bartlett DL, Vargas H, Walther M, Lubensky I et al. Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: Diagnostic and management recommendations. Surgery. 1998;124(6):1153–9. 10.1067/msy.1998.91823

13. Corcos O, Couvelard A, Giraud S, Vullierme MP, Dermot O’Toole, Rebours V et al. Endocrine pancreatic tumors in von Hippel-Lindau disease: Clinical, histological, and genetic features. Pancreas. 2008;37(1):85–93. 10.1097/MPA.0b013e31815f394a

14. Ehrlich Y, Beck SDW, Ulbright TM, Cheng L, Brames MJ, Andreoiu M et al. Outcome analysis of patients with transformed teratoma to primitive neuroectodermal tumor. Ann Oncol. 2010 Sep 1;21(9):1846–50. 10.1093/annonc/mdq045

15. Libutti SK, Choyke PL, Alexander HR, Glenn G, Bartlett DL, Zbar B et al. Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. Surgery. 2000;128(6):1022–7;1027. 10.1067/msy.2000.110239

16. Marcos HB, Libutti SK, Alexander HR, Lubensky IA, Bartlett DL, Walther MM et al. Neuroendocrine tumors of the pancreas in von Hippel-Lindau disease: Spectrum of appearances at CT and MR imaging with histopathologic comparison. Radiology. 2002;225(3):751–8. 10.1148/radiol.2253011297

17. Davenport MS, Caoili EM, Cohan RH, Hoff CN, Ellis JH. Pancreatic manifestations of von Hippel-Lindau disease-effect of imaging on clinical management. J Comput Assist Tomogr. 2010;34(4):517–22. 10.1097/RCT.0b013e3181d561e4

18. Blansfield JA, Choyke L, Morita SY, Choyke PL, Pingpank JF, Alexander HR et al. Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery. 2007;142(6):814–8;discussion 818.e1–2. 10.1016/j.surg.2007.09.012

19. Igarashi H, Ito T, Nishimori I, Tamura K, Yamasaki I, Tanaka M et al. Pancreatic involvement in Japanese patients with von Hippel-Lindau disease: Results of a nationwide survey. J Gastroenterol. 2014;49(3):511–6. 10.1007/s00535-013-0794-1

20. Park TY, Lee SK, Park JS, Oh D, Song TJ, Park DH et al. Clinical features of pancreatic involvement in von Hippel-Lindau disease: A retrospective study of 55 cases in a single center. Scand J Gastroenterol. 2015;50(3):360–7. 10.3109/00365521.2014.992364

21. Kos-Kudła B, Hubalewska-Dydejczyk A, Kus´nierz K, Lampe P, Marek B, Nasierowska-Guttmejer A, et al. Pancreatic neuroendocrine neoplasms—Management guidelines (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol. 2013;64(6):459–79. 10.5603/EP.2013.0031

22. Tamura K, Nishimori I, Ito T, Yamasaki I, Igarashi H, Shuin T. Diagnosis and management of pancreatic neuroendocrine tumor in von Hippel-Lindau disease. World J Gastroenterol. 2010;16(36):4515–8. 10.3748/wjg.v16.i36.4515

23. Benhammou JN, Boris RS, Pacak K, Pinto PA, Linehan WM, Bratslavsky G. Functional and oncologic outcomes of partial adrenalectomy for pheochromocytoma in patients with von Hippel-Lindau syndrome after at least 5 years of followup. J Urol. 2010;184(5):1855–9. 10.1016/j.juro.2010.06.102

24. Weil RJ, Lonser RR, DeVroom HL, Wanebo JE, Oldfield EH. Surgical management of brainstem hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg. 2003;98(1):95–105. 10.3171/jns.2003.98.1.0095

25. Mount SL, Weaver DL, Taatjes DJ, McKinnon WC, Hebert JC. Von Hippel-Lindau disease presenting as pancreatic neuroendocrine tumour. Virchows Arch. 1995;426(5):523–8. 10.1007/BF00193177

26. Choyke PL, Glenn GM, Walther MM, Patronas NJ, Linehan WM, Zbar B. von Hippel-Lindau disease: Genetic, clinical, and imaging features. Radiology. 1995;194(3):629–42. 10.1148/radiology.194.3.7862955

27. Solcia E, Capella C, Klöppel G. Tumors of the pancreas. In: Rosai J, Sobin LH, editors. Atlas of tumor pathology. 3rd series, fascicle 20. Washington, DC: Armed Forces Institute of Pathology; 1997. p. 145–209.

28. Neumann HPH, Dinkel E, Brambs H, Wimmer B, Friedburg H, Volk B et al. Pancreatic lesions in the von Hippel-Lindau syndrome. Gastroenterology. 1991;101(2):465–71. 10.1016/0016-5085(91)90026-h

29. Hough DM, Stephens DH, Johnson CD, Binkovitz LA. Pancreatic lesions in von Hippel-Lindau disease: Prevalence, clinical significance, and CT findings. AJR Am J Roentgenol. 1994;162(5):1091-4. 10.2214/ajr.162.5.8165988

30. Binkovitz LA, Johnson CD, Stephens DH. Islet cell tumors in von Hippel-Lindau disease: Increased prevalence and relationship to the multiple endocrine neoplasias. AJR Am J Roentgenol. 1990;155(3):501–5. 10.2214/ajr.155.3.1974734

31. Perez-Ordonez B, Naseem A, Lieberman PH, Klimstra DS. Solid serous adenoma of the pancreas. The solid variant of serous cystadenoma? Am J Surg Pathol. 1996;20(11):1401–5. 10.1097/00000478-199611000-00012

32. Zamboni G, Pea M, Martignoni G, Zancanaro C, Faccioli G, Gilioli E et al. Clear cell “sugar” tumor of the pancreas. A novel member of the family of lesions characterized by the presence of perivascular epithelioid cells. Am J Surg Pathol. 1996;20(6):722–30. 10.1097/00000478-199606000-00010

33. Padberg B, Schröder S, Capella C, Frilling A, Klöppel G, Heitz PU. Multiple endocrine neoplasia type 1 (MEN 1) revisited. Virchows Arch. 1995;426(6):541–8. 10.1007/BF00192107

34. Mulshine JL, Tubbs R, Sheeler LR, Gifford RW. Clinical significance of the association of the von Hippel-Lindau disease with pheochromocytoma and pancreatic apudoma. Am J Med Sci. 1984;288(5):212–6. 10.1097/00000441-198412000-00004

35. Knudson AG. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res. 1985;45(4):1437–43.

36. van Asselt SJ, Brouwers AH, van Dullemen HM, van der Jagt EJ, Bongaerts AH, Koopmans KP et al. Potential value of EUS in pancreatic surveillance of VHL patients. Eur J Endocrinol. 2016;174(5):611–20. 10.1530/EJE-15-1012

37. Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103(2):153–71. 10.1159/000443171

38. Keutgen XM, Hammel P, Choyke PL, Libutti SK, Jonasch E, Kebebew E. Evaluation and management of pancreatic lesions in patients with von Hippel-Lindau disease. Nat Rev Clin Oncol. 2016;13(9):537–49. 10.1038/nrclinonc.2016.37

39. Alliance VHL. The VHL handbook. 5th ed. Scotts Valley, CA, USA: CreateSpace Independent Publishing Platform; 2015.

40. Weisbrod AB, Kitano M, Gesuwan K, Millo C, Herscovitch P, Nilubol N et al. Clinical utility of functional imaging with 18F-FDOPA in von Hippel-Lindau syndrome. J Clin Endocrinol Metab. 2012;97(4):E613–7. 10.1210/jc.2011-2626

41. Weisbrod AB, Kitano M, Thomas F, Williams D, Gulati N, Gesuwan K et al. Assessment of tumor growth in pancreatic neuroendocrine tumors in von Hippel Lindau syndrome. J Am Coll Surg. 2014;218(2):163–9. 10.1016/j.jamcollsurg.2013.10.025

42. ClinicalTrials.gov. A study of Belzutifan (MK-6482) monotherapy in participants with advanced solid tumors (MK-6482-002). [cited 2023 March 31]. Avilable from: https://clinicaltrials.gov/ct2/show/NCT04195750

43. Liao J, et al. Exceptional activity of belzutifan (MK-6482) in metastatic pancreatic neuroendocrine tumors arising from von Hippel-Lindau disease. J Natl Compr Canc Netw. 2021;19(11):1343–7. 10.6004/jnccn.2021.7041

44. Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: peptide receptor radionuclide therapy with radiolabelled somatostatin analogues. Neuroendocrinology 2017;105:295-309. 10.1159/000475526